Astellas Pharma Inc (ALPMF) 14.1501 $ALPMF
Global Multiple Myeloma Drug Market & Pipeline Insight 2015
M2 - Mon May 18, 4:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8jtw5g/global_multiple) has announced the addition of the "Global Multiple Myeloma Drug Market & Pipeline Insight 2015" report to their offering. Multiple myeloma incidences are increasing across the globe and presently available therapeutics are unable to offer effective clinical benefits. Multiple myeloma chemotherapeutics shows modest pharmacological efficacy due to which necessity for better options are required. Surgery and radiation are equally ineffective and they are not viable for most of the cases. Pharmaceutical companies have identified this scenario due to which they are investing more funds in research and development segment. As a result, investigators would be able to screen more lead molecules for their safety and efficacy in multiple myeloma. Innovative modalities are being studied in clinical trial and they are expected to yield significant results thereby surpassing the issues related with presently available modalities in coming years. Several new developments are expected to take place in field of multiple myeloma segments in coming years. Technological advancements along with rising funding levels is expected to increase the rate of innovations for the development of multiple myeloma drug. As a result, their pipeline is expected to become strong and more clinical trials across the globe are expected to be instigated. Positive outcomes are expected from these clinical trials due to which volume of multiple myeloma therapeutics is going to increase. Simultaneously, there sales are also expected to increase due to profit erosion of presently available therapeutics. In this way, newly introduced multiple myeloma therapeutics are expected to increase several folds in coming years. Besides this, more patients are willing to pay for such therapeutics which can increase their disease free progression. "Global Multiple Myeloma Drug Market & Pipeline Insight 2015" Report Highlight: - Global Multiple Myeloma Drug Market Analysis - Global Multiple Myeloma Drug Clinical Insight by Company, Indication & Phase - Marketed Multiple Myeloma Drugs Clinical Insight - Mechanism of Multiple Myeloma Drug - Global Multiple Myeloma Drug Clinical Pipeline: 164 Drugs - Majority Multiple Myeloma Drugs in Phase-II Trials: 40 - Marketed Multiple Myeloma Drugs: 9 Competitive Landscape - AbbVie - Altor BioScience - Astellas Pharma - Astex Pharmaceuticals - Benovus Bio - Biogen Idec - Bristol-Myers Squibb - Celegen Pharmaceuticals - Cleave Biosciences - Genmab - Novartis - Onyx Pharmaceuticals - Pfizer - Millennium Pharmaceuticals - Vaxil Biotherapeutics For more information visit http://www.researchandmarkets.com/research/8j...l_multiple
BIIB: 395.42 (+4.18), BMY: 68.00 (+0.36), NVS: 104.06 (+0.31)
Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial
PR Newswire - Sun May 17, 11:52AM CDT
Astellas Pharma Inc. (TSE: 4503) announced today that results from its Phase 3b BESIDE clinical trial demonstrated solifenacin (SOLI) with mirabegron (MIRA) as an add-on therapy (ADD-ON) was superior to solifenacin monotherapy in incontinent overactive bladder (OAB) patients. The results of the BESIDE trial, which were presented today at the 2015 annual meeting of the American Urological Association (AUA), showed that the ADD-ON group achieved its primary efficacy endpoints.
Astellas And Medivation Announce New Enzalutamide Data Presented At The 2015 American Urological Association Annual Meeting
PR Newswire - Sun May 17, 11:48AM CDT
Astellas Pharma Inc (TSE:4503) and Medivation, Inc (NASDAQ: MDVN) today announced data from the Phase 2 STRIVE trial comparing enzalutamide and bicalutamide in non-metastatic (M0) and metastatic (M1) prostate cancer patients whose disease progressed despite treatment with a luteinizing hormone-releasing hormone (LHRH) analogue therapy or following surgical castration. The data were presented during an oral plenary session at the 2015 American Urological Association (AUA) annual meeting in New Orleans, Louisiana.
MDVN: 125.90 (+3.00)
Global Relapsed Multiple Myeloma Pipeline Report 2015
M2 - Thu May 14, 6:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xhk45j/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AB Science - AbbVie Inc. - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Arno Therapeutics, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Biotest AG - Bristol-Myers Squibb Company - Celgene Corporation - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Immunomedics, Inc. - Johnson & Johnson - Karyopharm Therapeutics, Inc. - MedImmune, LLC - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Onyx Pharmaceuticals, Inc. - Patrys Limited - Pfizer Inc. - Pharma Mar, S.A. - Pharmacyclics, Inc. - Prolexys Pharmaceuticals, Inc. - Sanofi - Threshold Pharmaceuticals, Inc. - Vivolux AB For more information visit http://www.researchandmarkets.com/research/xh...d_multiple
IMMU: 4.22 (+0.10), PCYC: 258.23 (+2.81), PFE: 33.98 (-0.01), BMY: 68.00 (+0.36), GSK: 44.66 (-0.11), JNJ: 103.42 (+1.12), MRK: 60.01 (-0.22), ABBV: 65.61 (-0.38), NVS: 104.06 (+0.31), KPTI: 27.02 (+2.21), XLRN: 32.68 (+0.84), ARRY: 7.50 (+0.27), CELGZ: 2.60 (unch)
Chronic Kidney Disease - Pipeline Analysis Covers Some of the Hot Targets in Research for Chronic Kidney Disease Treatments
M2 - Tue May 12, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rskhfs/chronic_kidney) has announced the addition of the "Chronic Kidney Disease - Pipeline Analysis" report to their offering. Chronic Kidney Disease (CKD) Pipeline Analysis gives comprehensive insight on the various drugs being developed for the treatment of CKD. The report covers all the drugs being developed in various phases (Discovery, Preclinical, Clinical & Marketing). The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules, monoclonal antibodies, stem cell therapies and RNA-based therapeutics, but excludes symptom relief drugs. This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the CKD Drug market. The report also provide strategic insights on medicines that are likely to have an impact on CKD treatment space and potentially alter standards of care in CKD in the foreseeable future. Current therapies are not effective and more than half of patients gradually face severe renal and cardiovascular complications, hence it provides a tremendous opportunity for upcoming therapies specific to CKD such as MAbs, stem cell-based and RNA-based therapies, which reverses disease course or slow down kidney deterioration. Companies Mentioned: - Angion Biomedica - Astellas Pharma - Astrazeneca - BLR Bio - Eli Lilly & Co - Johnson & Johnsonvidasyam Inc - Opko Health Inc - Pfizer - Regulus Therapeutics Key Topics Covered: 1. Report Description 2. Introduction 3. Hot Targets, Mechanisms and Therapies 4. Market Data 5. Pipeline Analysis 6. Small Molecules 7. Large Molecules 8. Monoclonal Antibodies 9. Stem Cell Therapy 10. RNA Based Therapeutics 11. Major Players 12. References For more information visit http://www.researchandmarkets.com/research/rs...nic_kidney About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OPK: 17.30 (+0.38), RGLS: 12.67 (+0.23), LLY: 72.94 (+0.04)
Cyclenium Pharma Announces Drug Discovery Collaboration Agreement with Astellas Pharma
Business Wire - Tue May 12, 3:00AM CDT
Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the discovery and development of novel drug candidates based on proprietary macrocyclic chemistry, announced today the signing of a drug discovery collaboration agreement with Astellas Pharma Inc., one of the world's leading pharmaceutical discovery and development companies. The collaboration, planned for an initial two year term, will exploit Cyclenium's proprietary QUEST Library(TM) of next generation synthetic small-molecule macrocycles and associated optimization expertise to identify clinical candidates effective against multiple pharmacological targets selected by Astellas in their therapeutic focus areas.
Vical Reports First Quarter 2015 Financial Results and Progress in Key Development Programs
GlobeNewswire - Fri May 08, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months ended March 31, 2015. Net loss for the first quarter of 2015 was $3.8 million, or $0.04 per share, compared with a net loss of $3.5 million, or $0.04 per share, for the first quarter of 2014. Revenues for the first quarter of 2015 were $4.9 million, compared with revenues of $2.4 million for the first quarter of 2014, reflecting higher revenues from Astellas Pharma Inc. for manufacturing services performed under our ASP0113 collaborative agreements. ASP0113 is Vical's therapeutic vaccine designed to prevent cytomegalovirus (CMV) disease and associated complications in transplant recipients.
VICL: 0.92 (-0.01)
Astellas and the Canadian National Transplant Research Program (CNTRP) Partner to Support Personalized Medicine Approaches to Improve Transplantation
CNW Group - Wed May 06, 8:00AM CDT
CNTRP and Astellas announce the first recipients of the Research Innovation Grant competition and a renewed commitment to research innovation
Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations
M2 - Tue May 05, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zfh5fn/asthma) has announced the addition of the "Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations" report to their offering. The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4% This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), and is a consequence of new market entrants and rising disease prevalence. The global prevalence of asthma is significant, believed to affect approximately 300 million people worldwide. This burden is predicted to increase in future, reaching 400 million by 2025. Although the majority of asthma patients are able to manage their symptoms effectively using currently marketed products, some remain inadequately controlled with these same products. This unmet need, coupled with rising global prevalence, has resulted in strong industry interest. Consequently, the current asthma pipeline is highly innovative, featuring several promising molecules in late-stage drug development. Biologics and monoclonal antibodies, the latter in particular, are gaining prominence within the indication. Novel monoclonal antibodies such as mepolizumab, reslizumab, lebrikizumab, and dupilumab target Interleukins (IL), or IL receptors, and have demonstrated potential in severe and inadequately controlled eosinophilic asthma, in turn representing a shift towards personalized therapy. Despite the fact that they target only a small patient sub-set, they are likely to be priced highly and to drive market growth, offsetting the impact of generic erosion. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed Products 4 Asthma Pipeline 5 Market Forecast to 2020 6 Strategic Consolidations 7 Appendix Companies Featured: - AB Science - Amgen - Aslan Pharma - Astellas Pharma - AstraZeneca - Boehringer Ingelheim - CSL - GSK - Genentech - GlaxoSmithKline/Theravance - Janssen Pharmaceuticals - Kyowa Hakko Kirin - MAP Pharmaceuticals - Merck - Mundipharma - NeoStem - Novartis - Nycomed - Orexo - Regeneron Pharmaceuticals - Roche/Genentech - Sanofi - Sepracor - SkyePharma - Teva Pharmaceutical - University of California For more information visit http://www.researchandmarkets.com/research/zfh5fn/asthma
MRK: 60.01 (-0.22), AMGN: 163.44 (+1.08), GSK: 44.66 (-0.11), REGN: 496.74 (+7.73), NVS: 104.06 (+0.31)
Invivoscribe Technologies Announces Companion Diagnostic Agreement
Marketwired - Tue Apr 28, 7:09AM CDT
Invivoscribe(R) Technologies, Inc., a company with international experience commercializing in vitro diagnostic tests and developing companion diagnostics, today announced they have entered into a companion diagnostic agreement with Astellas Pharma Inc.
Neuropathy Partnering Deals and Agreements Analysis 2010-2015
M2 - Mon Apr 27, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zf2xtc/neuropathy) has announced the addition of the "Neuropathy Partnering 2010-2015" report to their offering. The Neuropathy Partnering 2010-2015 provides understanding and access to the neuropathy partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of neuropathy partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors neuropathy technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 30 links to online copies of actual neuropathy deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. This data driven report includes: - Trends in neuropathy dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 30 neuropathy deals and contract documents where available - The leading neuropathy deals by value since 2010 In Neuropathy Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Companies Mentioned - Abbott - Abbvie - Actavis - Watson Pharmaceuticals - Allergan - Amgen - Astellas - Astellas Pharma US - AstraZeneca - Baxter International - Bayer - Chugai Pharma Marketing - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eisai Inc - Janssen Research & Development - Kyowa Hakko Kirin - Lundbeck - Merck KGaA - Sanofi-Aventis - Sanofi-Pasteur - Servier - Shionogi - BioMarin Pharmaceuticals - Cangene - Cubist - Dendreon - Elan - Emergent BioSolutions - Galapagos - Genmab - Grifols For more information visit http://www.researchandmarkets.com/research/zf2xtc/neuropathy
AGN: 240.22 (+2.88), EBS: 30.91 (+0.19), BAX: 68.25 (-1.11), AMGN: 163.44 (+1.08)
Thrombus Partnering Deals and Agreements Analysis 2010-2015
M2 - Mon Apr 27, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s2fhv9/thrombus) has announced the addition of the "Thrombus Partnering 2010-2015" report to their offering. The Thrombus Partnering 2010-2015 provides understanding and access to the thrombus partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of thrombus partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors thrombus technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 35 links to online copies of actual thrombus deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. This data driven report includes: - Trends in thrombus dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 35 thrombus deals and contract documents where available - The leading thrombus deals by value since 2010 In Thrombus Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Companies Mentioned: - Abbott - Abbvie - Actavis - Watson Pharmaceuticals - Allergan - Amgen - Astellas - Astellas Pharma US - AstraZeneca - Baxter International - Bayer - Chugai Pharma Marketing - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eisai Inc - Janssen Research & Development - Kyowa Hakko Kirin - Lundbeck - Merck KGaA - Sanofi-Aventis - Sanofi-Pasteur - Servier - Shionogi - BioMarin Pharmaceuticals - Cangene - Cubist - Dendreon - Elan - Emergent BioSolutions - Galapagos - Genmab - Grifols For more information visit http://www.researchandmarkets.com/research/s2fhv9/thrombus
AGN: 240.22 (+2.88), EBS: 30.91 (+0.19), BAX: 68.25 (-1.11), AMGN: 163.44 (+1.08)
Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2015
M2 - Mon Apr 27, 8:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/334b6p/clinical_stage) has announced the addition of the "Clinical Stage Partnering Terms and Agreements in Pharma and Biotech" report to their offering. The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the clinical stage partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This report contains over 2,000 links to online copies of actual clinical stage deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Why do companies partner clinical stage compounds? Chapter 3 - Clinical stage deal strategies and structure Chapter 4 - Clinical stage partnering payment strategies Chapter 5 - Trends in clinical stage deal making Chapter 6 - Average payment terms for clinical stage partnering Chapter 7 - Leading clinical stage deals Chapter 8 - Big pharma and big biotech clinical stage partnering deals Chapter 9 - Clinical stage partnering contracts directory Chapter 10 - Clinical stage dealmaking by development stage Companies Featured (Partial List) - Abbott - Abbvie - Actavis - Watson Pharmaceuticals - Allergan - Amgen - Astellas - Astellas Pharma US - AstraZeneca - Baxter International - Bayer - Chugai Pharma Marketing - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eisai Inc - Janssen Research & Development - Kyowa Hakko Kirin - Lundbeck - Merck KGaA - Sanofi-Aventis - Sanofi-Pasteur - Servier - Shionogi - BioMarin Pharmaceuticals - Cangene - Cubist - Dendreon - Elan - Emergent BioSolutions - Galapagos - Genmab - Grifols For more information visit http://www.researchandmarkets.com/research/33...ical_stage
AGN: 240.22 (+2.88), EBS: 30.91 (+0.19), BAX: 68.25 (-1.11), AMGN: 163.44 (+1.08)
Astellas Pharma and Potenza Therapeutics Partner to Build a Portfolio of Immuno-oncology Therapeutics
Business Wire - Tue Apr 21, 6:30PM CDT
Astellas Pharma Inc. (Tokyo: 4503) and Potenza Therapeutics, Inc., a biotechnology company developing a portfolio of immuno-oncology programs, today announced an exclusive research and development collaboration. The goal of the collaboration is to advance a portfolio consisting of programs with novel mechanisms of action targeting immune checkpoint pathways, co-stimulatory signals and regulatory T cells. The agreement includes an option that allows for the future acquisition of Potenza by Astellas on pre-determined terms at the end of the collaboration period.
Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology Therapeutics
PR Newswire - Tue Apr 21, 6:30PM CDT
Astellas Pharma Inc. (Tokyo: 4503) and Potenza Therapeutics, Inc., a biotechnology company developing a portfolio of immuno-oncology programs, today announced an exclusive research and development collaboration. The goal of the collaboration is to advance a portfolio consisting of programs with novel mechanisms of action targeting immune checkpoint pathways, co-stimulatory signals and regulatory T cells. The agreement includes an option that allows for the future acquisition of Potenza by Astellas on pre-determined terms at the end of the collaboration period.
How To Play Japanese Monopoly
Matthew Waterman - at Seeking Alpha - Tue Apr 21, 5:08AM CDT
SNE: 32.45 (-0.29), TM: 139.43 (+0.06), DCM: 18.39 (+0.11), MFG: 4.12 (+0.09), MAT: 26.28 (-0.67), SMFG: 8.85 (+0.19), S: 4.81 (-0.01), HMC: 35.20 (+0.20), MSFT: 48.01 (-0.28), KNM: 19.29 (+0.36), MTU: 7.60 (+0.37)
Finding Biopharma Licensing and Collaboration Partners: 2015 Guide
M2 - Thu Apr 16, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lwvpxl/finding_biopharma) has announced the addition of the "Finding Biopharma Licensing and Collaboration Partners" report to their offering. The report takes the reader through the practical steps required to prepare for partnering, prepare supporting materials, identify and shortlist potential partners and opportunities, identifying and contacting the right person in the partner company, and managing of discussions through to deal negotiation. In addition, the report provides a detailed overview of the activities a business development executive and a company should be undertaking to build and maintain an extensive contact network, and to become partner of choice, respectively. The report is structured to take the reader step by step through the process of finding and securing partners. However, each chapter is also acts an easy access reference to the particular activity. The report contains numerous checklists and summaries of the contents of key documents required during the partnering process. The report is also provides numerous insights drawn from extensive direct industry experience and knowledge of the author and others. The report provides numerous examples of actual information sources and actual materials utilized by biopharma companies during their partnering efforts, allowing the reader to act on the contents of the report in order to improve their own partnering processes and activities. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Overview of the partnering process Chapter 3 - Identifying in-licensing opportunities Chapter 4 - Identifying partners Chapter 5 - Building and maintaining a partnering network Chapter 6 - Packaging your offering Chapter 7 - Making contact Companies Mentioned - Partial List - Abbott Japan - Abbott Laboratories - Abraxis BioScience - ACADIA Pharmaceuticals - Acceleron Pharma - Achillion Pharmaceuticals - Adnexus Therapeutics - Adolor - AEterna Zentaris - Affymax - Agensys - Alfacell - Allergan - Ambit Biosciences - Amgen - Amylin Pharmaceuticals - Anacor Pharmaceuticals - Anesiva - Archemix - Ariad Pharmaceuticals - ArQule - Array Biopharma - ARYx Therapeutics - Astellas Pharma - AstraZeneca - Athersys For more information visit http://www.researchandmarkets.com/research/lw..._biopharma
ABT: 48.84 (+0.13), AMGN: 163.44 (+1.08), AGN: 240.22 (+2.88), ACAD: 40.31 (+1.14), ACHN: 11.03 (+1.46), AEZS: 0.42 (-0.01), ANAC: 61.89 (-0.48), XLRN: 32.68 (+0.84)
Health Canada Approves New Indication for the Use of Xtandi® (enzalutamide) Capsules for Patients with Metastatic Castration-Resistant Prostate Cancer
CNW Group - Thu Apr 16, 7:00AM CDT
Approval based on improved overall survival, delayed time to radiographic progression and an overall positive risk-benefit profile
MDVN: 125.90 (+3.00)
Ventana Medical Systems, Inc. and Astellas Pharma join forces to leverage novel companion diagnostic tests for targeted cancer treatments
PR Newswire Europe - Tue Apr 14, 9:01AM CDT
Ventana Medical Systems, Inc. [http://www.ventana.com/] (Ventana), a member of the Roche [http://www.roche.com/index.htm] Group, today announced it has entered into master collaboration agreement with Astellas Pharma Inc., an R&D-driven global pharmaceutical company headquartered in Japan, to develop novel automated tissue diagnostics in support of therapeutic compounds in development.
Global Multiple Myeloma Drug Market & Pipeline Insight 2015
M2 - Mon May 18, 4:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8jtw5g/global_multiple) has announced the addition of the "Global Multiple Myeloma Drug Market & Pipeline Insight 2015" report to their offering. Multiple myeloma incidences are increasing across the globe and presently available therapeutics are unable to offer effective clinical benefits. Multiple myeloma chemotherapeutics shows modest pharmacological efficacy due to which necessity for better options are required. Surgery and radiation are equally ineffective and they are not viable for most of the cases. Pharmaceutical companies have identified this scenario due to which they are investing more funds in research and development segment. As a result, investigators would be able to screen more lead molecules for their safety and efficacy in multiple myeloma. Innovative modalities are being studied in clinical trial and they are expected to yield significant results thereby surpassing the issues related with presently available modalities in coming years. Several new developments are expected to take place in field of multiple myeloma segments in coming years. Technological advancements along with rising funding levels is expected to increase the rate of innovations for the development of multiple myeloma drug. As a result, their pipeline is expected to become strong and more clinical trials across the globe are expected to be instigated. Positive outcomes are expected from these clinical trials due to which volume of multiple myeloma therapeutics is going to increase. Simultaneously, there sales are also expected to increase due to profit erosion of presently available therapeutics. In this way, newly introduced multiple myeloma therapeutics are expected to increase several folds in coming years. Besides this, more patients are willing to pay for such therapeutics which can increase their disease free progression. "Global Multiple Myeloma Drug Market & Pipeline Insight 2015" Report Highlight: - Global Multiple Myeloma Drug Market Analysis - Global Multiple Myeloma Drug Clinical Insight by Company, Indication & Phase - Marketed Multiple Myeloma Drugs Clinical Insight - Mechanism of Multiple Myeloma Drug - Global Multiple Myeloma Drug Clinical Pipeline: 164 Drugs - Majority Multiple Myeloma Drugs in Phase-II Trials: 40 - Marketed Multiple Myeloma Drugs: 9 Competitive Landscape - AbbVie - Altor BioScience - Astellas Pharma - Astex Pharmaceuticals - Benovus Bio - Biogen Idec - Bristol-Myers Squibb - Celegen Pharmaceuticals - Cleave Biosciences - Genmab - Novartis - Onyx Pharmaceuticals - Pfizer - Millennium Pharmaceuticals - Vaxil Biotherapeutics For more information visit http://www.researchandmarkets.com/research/8j...l_multiple
BIIB: 395.42 (+4.18), BMY: 68.00 (+0.36), NVS: 104.06 (+0.31)
Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial
PR Newswire - Sun May 17, 11:52AM CDT
Astellas Pharma Inc. (TSE: 4503) announced today that results from its Phase 3b BESIDE clinical trial demonstrated solifenacin (SOLI) with mirabegron (MIRA) as an add-on therapy (ADD-ON) was superior to solifenacin monotherapy in incontinent overactive bladder (OAB) patients. The results of the BESIDE trial, which were presented today at the 2015 annual meeting of the American Urological Association (AUA), showed that the ADD-ON group achieved its primary efficacy endpoints.
Astellas And Medivation Announce New Enzalutamide Data Presented At The 2015 American Urological Association Annual Meeting
PR Newswire - Sun May 17, 11:48AM CDT
Astellas Pharma Inc (TSE:4503) and Medivation, Inc (NASDAQ: MDVN) today announced data from the Phase 2 STRIVE trial comparing enzalutamide and bicalutamide in non-metastatic (M0) and metastatic (M1) prostate cancer patients whose disease progressed despite treatment with a luteinizing hormone-releasing hormone (LHRH) analogue therapy or following surgical castration. The data were presented during an oral plenary session at the 2015 American Urological Association (AUA) annual meeting in New Orleans, Louisiana.
MDVN: 125.90 (+3.00)
Global Relapsed Multiple Myeloma Pipeline Report 2015
M2 - Thu May 14, 6:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xhk45j/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AB Science - AbbVie Inc. - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Arno Therapeutics, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Biotest AG - Bristol-Myers Squibb Company - Celgene Corporation - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Immunomedics, Inc. - Johnson & Johnson - Karyopharm Therapeutics, Inc. - MedImmune, LLC - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Onyx Pharmaceuticals, Inc. - Patrys Limited - Pfizer Inc. - Pharma Mar, S.A. - Pharmacyclics, Inc. - Prolexys Pharmaceuticals, Inc. - Sanofi - Threshold Pharmaceuticals, Inc. - Vivolux AB For more information visit http://www.researchandmarkets.com/research/xh...d_multiple
IMMU: 4.22 (+0.10), PCYC: 258.23 (+2.81), PFE: 33.98 (-0.01), BMY: 68.00 (+0.36), GSK: 44.66 (-0.11), JNJ: 103.42 (+1.12), MRK: 60.01 (-0.22), ABBV: 65.61 (-0.38), NVS: 104.06 (+0.31), KPTI: 27.02 (+2.21), XLRN: 32.68 (+0.84), ARRY: 7.50 (+0.27), CELGZ: 2.60 (unch)
Chronic Kidney Disease - Pipeline Analysis Covers Some of the Hot Targets in Research for Chronic Kidney Disease Treatments
M2 - Tue May 12, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rskhfs/chronic_kidney) has announced the addition of the "Chronic Kidney Disease - Pipeline Analysis" report to their offering. Chronic Kidney Disease (CKD) Pipeline Analysis gives comprehensive insight on the various drugs being developed for the treatment of CKD. The report covers all the drugs being developed in various phases (Discovery, Preclinical, Clinical & Marketing). The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules, monoclonal antibodies, stem cell therapies and RNA-based therapeutics, but excludes symptom relief drugs. This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the CKD Drug market. The report also provide strategic insights on medicines that are likely to have an impact on CKD treatment space and potentially alter standards of care in CKD in the foreseeable future. Current therapies are not effective and more than half of patients gradually face severe renal and cardiovascular complications, hence it provides a tremendous opportunity for upcoming therapies specific to CKD such as MAbs, stem cell-based and RNA-based therapies, which reverses disease course or slow down kidney deterioration. Companies Mentioned: - Angion Biomedica - Astellas Pharma - Astrazeneca - BLR Bio - Eli Lilly & Co - Johnson & Johnsonvidasyam Inc - Opko Health Inc - Pfizer - Regulus Therapeutics Key Topics Covered: 1. Report Description 2. Introduction 3. Hot Targets, Mechanisms and Therapies 4. Market Data 5. Pipeline Analysis 6. Small Molecules 7. Large Molecules 8. Monoclonal Antibodies 9. Stem Cell Therapy 10. RNA Based Therapeutics 11. Major Players 12. References For more information visit http://www.researchandmarkets.com/research/rs...nic_kidney About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OPK: 17.30 (+0.38), RGLS: 12.67 (+0.23), LLY: 72.94 (+0.04)
Cyclenium Pharma Announces Drug Discovery Collaboration Agreement with Astellas Pharma
Business Wire - Tue May 12, 3:00AM CDT
Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the discovery and development of novel drug candidates based on proprietary macrocyclic chemistry, announced today the signing of a drug discovery collaboration agreement with Astellas Pharma Inc., one of the world's leading pharmaceutical discovery and development companies. The collaboration, planned for an initial two year term, will exploit Cyclenium's proprietary QUEST Library(TM) of next generation synthetic small-molecule macrocycles and associated optimization expertise to identify clinical candidates effective against multiple pharmacological targets selected by Astellas in their therapeutic focus areas.
Vical Reports First Quarter 2015 Financial Results and Progress in Key Development Programs
GlobeNewswire - Fri May 08, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months ended March 31, 2015. Net loss for the first quarter of 2015 was $3.8 million, or $0.04 per share, compared with a net loss of $3.5 million, or $0.04 per share, for the first quarter of 2014. Revenues for the first quarter of 2015 were $4.9 million, compared with revenues of $2.4 million for the first quarter of 2014, reflecting higher revenues from Astellas Pharma Inc. for manufacturing services performed under our ASP0113 collaborative agreements. ASP0113 is Vical's therapeutic vaccine designed to prevent cytomegalovirus (CMV) disease and associated complications in transplant recipients.
VICL: 0.92 (-0.01)
Astellas and the Canadian National Transplant Research Program (CNTRP) Partner to Support Personalized Medicine Approaches to Improve Transplantation
CNW Group - Wed May 06, 8:00AM CDT
CNTRP and Astellas announce the first recipients of the Research Innovation Grant competition and a renewed commitment to research innovation
Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations
M2 - Tue May 05, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zfh5fn/asthma) has announced the addition of the "Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations" report to their offering. The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4% This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), and is a consequence of new market entrants and rising disease prevalence. The global prevalence of asthma is significant, believed to affect approximately 300 million people worldwide. This burden is predicted to increase in future, reaching 400 million by 2025. Although the majority of asthma patients are able to manage their symptoms effectively using currently marketed products, some remain inadequately controlled with these same products. This unmet need, coupled with rising global prevalence, has resulted in strong industry interest. Consequently, the current asthma pipeline is highly innovative, featuring several promising molecules in late-stage drug development. Biologics and monoclonal antibodies, the latter in particular, are gaining prominence within the indication. Novel monoclonal antibodies such as mepolizumab, reslizumab, lebrikizumab, and dupilumab target Interleukins (IL), or IL receptors, and have demonstrated potential in severe and inadequately controlled eosinophilic asthma, in turn representing a shift towards personalized therapy. Despite the fact that they target only a small patient sub-set, they are likely to be priced highly and to drive market growth, offsetting the impact of generic erosion. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed Products 4 Asthma Pipeline 5 Market Forecast to 2020 6 Strategic Consolidations 7 Appendix Companies Featured: - AB Science - Amgen - Aslan Pharma - Astellas Pharma - AstraZeneca - Boehringer Ingelheim - CSL - GSK - Genentech - GlaxoSmithKline/Theravance - Janssen Pharmaceuticals - Kyowa Hakko Kirin - MAP Pharmaceuticals - Merck - Mundipharma - NeoStem - Novartis - Nycomed - Orexo - Regeneron Pharmaceuticals - Roche/Genentech - Sanofi - Sepracor - SkyePharma - Teva Pharmaceutical - University of California For more information visit http://www.researchandmarkets.com/research/zfh5fn/asthma
MRK: 60.01 (-0.22), AMGN: 163.44 (+1.08), GSK: 44.66 (-0.11), REGN: 496.74 (+7.73), NVS: 104.06 (+0.31)
Invivoscribe Technologies Announces Companion Diagnostic Agreement
Marketwired - Tue Apr 28, 7:09AM CDT
Invivoscribe(R) Technologies, Inc., a company with international experience commercializing in vitro diagnostic tests and developing companion diagnostics, today announced they have entered into a companion diagnostic agreement with Astellas Pharma Inc.
Neuropathy Partnering Deals and Agreements Analysis 2010-2015
M2 - Mon Apr 27, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zf2xtc/neuropathy) has announced the addition of the "Neuropathy Partnering 2010-2015" report to their offering. The Neuropathy Partnering 2010-2015 provides understanding and access to the neuropathy partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of neuropathy partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors neuropathy technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 30 links to online copies of actual neuropathy deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. This data driven report includes: - Trends in neuropathy dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 30 neuropathy deals and contract documents where available - The leading neuropathy deals by value since 2010 In Neuropathy Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Companies Mentioned - Abbott - Abbvie - Actavis - Watson Pharmaceuticals - Allergan - Amgen - Astellas - Astellas Pharma US - AstraZeneca - Baxter International - Bayer - Chugai Pharma Marketing - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eisai Inc - Janssen Research & Development - Kyowa Hakko Kirin - Lundbeck - Merck KGaA - Sanofi-Aventis - Sanofi-Pasteur - Servier - Shionogi - BioMarin Pharmaceuticals - Cangene - Cubist - Dendreon - Elan - Emergent BioSolutions - Galapagos - Genmab - Grifols For more information visit http://www.researchandmarkets.com/research/zf2xtc/neuropathy
AGN: 240.22 (+2.88), EBS: 30.91 (+0.19), BAX: 68.25 (-1.11), AMGN: 163.44 (+1.08)
Thrombus Partnering Deals and Agreements Analysis 2010-2015
M2 - Mon Apr 27, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s2fhv9/thrombus) has announced the addition of the "Thrombus Partnering 2010-2015" report to their offering. The Thrombus Partnering 2010-2015 provides understanding and access to the thrombus partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of thrombus partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors thrombus technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 35 links to online copies of actual thrombus deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. This data driven report includes: - Trends in thrombus dealmaking in the biopharma industry since 2010 - Access to summary headline, upfront, milestone and royalty data - Access to over 35 thrombus deals and contract documents where available - The leading thrombus deals by value since 2010 In Thrombus Partnering 2010-2015, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Companies Mentioned: - Abbott - Abbvie - Actavis - Watson Pharmaceuticals - Allergan - Amgen - Astellas - Astellas Pharma US - AstraZeneca - Baxter International - Bayer - Chugai Pharma Marketing - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eisai Inc - Janssen Research & Development - Kyowa Hakko Kirin - Lundbeck - Merck KGaA - Sanofi-Aventis - Sanofi-Pasteur - Servier - Shionogi - BioMarin Pharmaceuticals - Cangene - Cubist - Dendreon - Elan - Emergent BioSolutions - Galapagos - Genmab - Grifols For more information visit http://www.researchandmarkets.com/research/s2fhv9/thrombus
AGN: 240.22 (+2.88), EBS: 30.91 (+0.19), BAX: 68.25 (-1.11), AMGN: 163.44 (+1.08)
Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2015
M2 - Mon Apr 27, 8:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/334b6p/clinical_stage) has announced the addition of the "Clinical Stage Partnering Terms and Agreements in Pharma and Biotech" report to their offering. The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the clinical stage partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This report contains over 2,000 links to online copies of actual clinical stage deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Why do companies partner clinical stage compounds? Chapter 3 - Clinical stage deal strategies and structure Chapter 4 - Clinical stage partnering payment strategies Chapter 5 - Trends in clinical stage deal making Chapter 6 - Average payment terms for clinical stage partnering Chapter 7 - Leading clinical stage deals Chapter 8 - Big pharma and big biotech clinical stage partnering deals Chapter 9 - Clinical stage partnering contracts directory Chapter 10 - Clinical stage dealmaking by development stage Companies Featured (Partial List) - Abbott - Abbvie - Actavis - Watson Pharmaceuticals - Allergan - Amgen - Astellas - Astellas Pharma US - AstraZeneca - Baxter International - Bayer - Chugai Pharma Marketing - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eisai Inc - Janssen Research & Development - Kyowa Hakko Kirin - Lundbeck - Merck KGaA - Sanofi-Aventis - Sanofi-Pasteur - Servier - Shionogi - BioMarin Pharmaceuticals - Cangene - Cubist - Dendreon - Elan - Emergent BioSolutions - Galapagos - Genmab - Grifols For more information visit http://www.researchandmarkets.com/research/33...ical_stage
AGN: 240.22 (+2.88), EBS: 30.91 (+0.19), BAX: 68.25 (-1.11), AMGN: 163.44 (+1.08)
Astellas Pharma and Potenza Therapeutics Partner to Build a Portfolio of Immuno-oncology Therapeutics
Business Wire - Tue Apr 21, 6:30PM CDT
Astellas Pharma Inc. (Tokyo: 4503) and Potenza Therapeutics, Inc., a biotechnology company developing a portfolio of immuno-oncology programs, today announced an exclusive research and development collaboration. The goal of the collaboration is to advance a portfolio consisting of programs with novel mechanisms of action targeting immune checkpoint pathways, co-stimulatory signals and regulatory T cells. The agreement includes an option that allows for the future acquisition of Potenza by Astellas on pre-determined terms at the end of the collaboration period.
Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology Therapeutics
PR Newswire - Tue Apr 21, 6:30PM CDT
Astellas Pharma Inc. (Tokyo: 4503) and Potenza Therapeutics, Inc., a biotechnology company developing a portfolio of immuno-oncology programs, today announced an exclusive research and development collaboration. The goal of the collaboration is to advance a portfolio consisting of programs with novel mechanisms of action targeting immune checkpoint pathways, co-stimulatory signals and regulatory T cells. The agreement includes an option that allows for the future acquisition of Potenza by Astellas on pre-determined terms at the end of the collaboration period.
How To Play Japanese Monopoly
Matthew Waterman - at Seeking Alpha - Tue Apr 21, 5:08AM CDT
SNE: 32.45 (-0.29), TM: 139.43 (+0.06), DCM: 18.39 (+0.11), MFG: 4.12 (+0.09), MAT: 26.28 (-0.67), SMFG: 8.85 (+0.19), S: 4.81 (-0.01), HMC: 35.20 (+0.20), MSFT: 48.01 (-0.28), KNM: 19.29 (+0.36), MTU: 7.60 (+0.37)
Finding Biopharma Licensing and Collaboration Partners: 2015 Guide
M2 - Thu Apr 16, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lwvpxl/finding_biopharma) has announced the addition of the "Finding Biopharma Licensing and Collaboration Partners" report to their offering. The report takes the reader through the practical steps required to prepare for partnering, prepare supporting materials, identify and shortlist potential partners and opportunities, identifying and contacting the right person in the partner company, and managing of discussions through to deal negotiation. In addition, the report provides a detailed overview of the activities a business development executive and a company should be undertaking to build and maintain an extensive contact network, and to become partner of choice, respectively. The report is structured to take the reader step by step through the process of finding and securing partners. However, each chapter is also acts an easy access reference to the particular activity. The report contains numerous checklists and summaries of the contents of key documents required during the partnering process. The report is also provides numerous insights drawn from extensive direct industry experience and knowledge of the author and others. The report provides numerous examples of actual information sources and actual materials utilized by biopharma companies during their partnering efforts, allowing the reader to act on the contents of the report in order to improve their own partnering processes and activities. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Overview of the partnering process Chapter 3 - Identifying in-licensing opportunities Chapter 4 - Identifying partners Chapter 5 - Building and maintaining a partnering network Chapter 6 - Packaging your offering Chapter 7 - Making contact Companies Mentioned - Partial List - Abbott Japan - Abbott Laboratories - Abraxis BioScience - ACADIA Pharmaceuticals - Acceleron Pharma - Achillion Pharmaceuticals - Adnexus Therapeutics - Adolor - AEterna Zentaris - Affymax - Agensys - Alfacell - Allergan - Ambit Biosciences - Amgen - Amylin Pharmaceuticals - Anacor Pharmaceuticals - Anesiva - Archemix - Ariad Pharmaceuticals - ArQule - Array Biopharma - ARYx Therapeutics - Astellas Pharma - AstraZeneca - Athersys For more information visit http://www.researchandmarkets.com/research/lw..._biopharma
ABT: 48.84 (+0.13), AMGN: 163.44 (+1.08), AGN: 240.22 (+2.88), ACAD: 40.31 (+1.14), ACHN: 11.03 (+1.46), AEZS: 0.42 (-0.01), ANAC: 61.89 (-0.48), XLRN: 32.68 (+0.84)
Health Canada Approves New Indication for the Use of Xtandi® (enzalutamide) Capsules for Patients with Metastatic Castration-Resistant Prostate Cancer
CNW Group - Thu Apr 16, 7:00AM CDT
Approval based on improved overall survival, delayed time to radiographic progression and an overall positive risk-benefit profile
MDVN: 125.90 (+3.00)
Ventana Medical Systems, Inc. and Astellas Pharma join forces to leverage novel companion diagnostic tests for targeted cancer treatments
PR Newswire Europe - Tue Apr 14, 9:01AM CDT
Ventana Medical Systems, Inc. [http://www.ventana.com/] (Ventana), a member of the Roche [http://www.roche.com/index.htm] Group, today announced it has entered into master collaboration agreement with Astellas Pharma Inc., an R&D-driven global pharmaceutical company headquartered in Japan, to develop novel automated tissue diagnostics in support of therapeutic compounds in development.
